WO2020186111A3 - Anticorps se liant à vista et leurs utilisations - Google Patents
Anticorps se liant à vista et leurs utilisations Download PDFInfo
- Publication number
- WO2020186111A3 WO2020186111A3 PCT/US2020/022476 US2020022476W WO2020186111A3 WO 2020186111 A3 WO2020186111 A3 WO 2020186111A3 US 2020022476 W US2020022476 W US 2020022476W WO 2020186111 A3 WO2020186111 A3 WO 2020186111A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vista
- binding antibodies
- antibodies
- cancer
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention concerne des procédés thérapeutiques d'utilisation d'anticorps anti-VISTA dans le traitement de maladies telles que le cancer.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962817242P | 2019-03-12 | 2019-03-12 | |
US62/817,242 | 2019-03-12 | ||
US201962828259P | 2019-04-02 | 2019-04-02 | |
US62/828,259 | 2019-04-02 | ||
US201962869507P | 2019-07-01 | 2019-07-01 | |
US62/869,507 | 2019-07-01 | ||
US201962914355P | 2019-10-11 | 2019-10-11 | |
US62/914,355 | 2019-10-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2020186111A2 WO2020186111A2 (fr) | 2020-09-17 |
WO2020186111A3 true WO2020186111A3 (fr) | 2020-10-15 |
Family
ID=72427103
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2020/022476 WO2020186111A2 (fr) | 2019-03-12 | 2020-03-12 | Anticorps se liant à vista et leurs utilisations |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2020186111A2 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB202108446D0 (en) * | 2021-06-14 | 2021-07-28 | Hummingbird Bioscience Holdings Pte Ltd | Cells expressing VISTA antigen-binding molecules |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110287002A1 (en) * | 2010-05-04 | 2011-11-24 | Adimab, Llc | Antibodies against epidermal growth factor receptor (egfr) and uses thereof |
US20140271617A1 (en) * | 2011-09-30 | 2014-09-18 | Chugai Seiyaku Kabushiki Kaisha | Ion concentration-dependent binding molecule library |
WO2018027042A1 (fr) * | 2016-08-03 | 2018-02-08 | Bio-Techne Corporation | Identification de vsig3/vista comme nouveau point de contrôle immunitaire et son utilisation en immunothérapie |
-
2020
- 2020-03-12 WO PCT/US2020/022476 patent/WO2020186111A2/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110287002A1 (en) * | 2010-05-04 | 2011-11-24 | Adimab, Llc | Antibodies against epidermal growth factor receptor (egfr) and uses thereof |
US20140271617A1 (en) * | 2011-09-30 | 2014-09-18 | Chugai Seiyaku Kabushiki Kaisha | Ion concentration-dependent binding molecule library |
WO2018027042A1 (fr) * | 2016-08-03 | 2018-02-08 | Bio-Techne Corporation | Identification de vsig3/vista comme nouveau point de contrôle immunitaire et son utilisation en immunothérapie |
Also Published As
Publication number | Publication date |
---|---|
WO2020186111A2 (fr) | 2020-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018190719A3 (fr) | Anticorps anti-sirp alpha | |
WO2018089508A3 (fr) | Anticorps anti-cd47 | |
WO2019224716A8 (fr) | Anticorps spécifiques de gucy2c et leurs utilisations | |
WO2018017864A3 (fr) | Agents de liaison à pvrig et leurs utilisations | |
WO2017134302A3 (fr) | Agents thérapeutiques ciblés et leurs utilisations | |
WO2018033254A3 (fr) | Arn pour la cancérothérapie | |
WO2016191643A3 (fr) | Agents de liaison à tigit et leurs utilisations | |
WO2018170338A3 (fr) | Tcr spécifiques de mage-a1 à haute affinité et leurs utilisations | |
EP3668497A4 (fr) | Procédés et compositions de traitement de maladies associées au cancer, à une inflammation ou à une réponse immunitaire | |
CA3055791A1 (fr) | Procedes de traitement | |
WO2017136820A3 (fr) | Technologie fit-immunoglobuline et ses utilisations | |
PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
WO2017049038A3 (fr) | Anticorps anti-cd115 | |
WO2017214170A3 (fr) | Anticorps baff-r et utilisations de ceux-ci | |
MX2021011723A (es) | Ligandos de pseudocinasa tyk2. | |
MX2021009555A (es) | Ligandos de pseudocinasa tyk2. | |
EP3761970A4 (fr) | Compositions et procédés pour le traitement de maladies neurologiques | |
MX2021007235A (es) | Tubulisinas y conjugados de proteina-tubulisina. | |
WO2019209965A3 (fr) | Protéines de fusion de l'interleukine 12, et compositions et procédés thérapeutiques associés | |
WO2018069871A3 (fr) | Protéines de liaison anti-kras | |
EP3969597A4 (fr) | Compositions et procédés pour le traitement de maladies médiées par l'atpase | |
EP3969125A4 (fr) | Utilisation d'anticorps anti-fcrn dans le traitement du pemphighus et de maladies du pemphigoïde | |
WO2020180712A8 (fr) | Anticorps anti-tnfr2 et leurs utilisations | |
MX2018009499A (es) | Anticuerpos monoclonales especificos de egfl6 y metodos de su uso. | |
MX2022005563A (es) | Ligandos de la pseudoquinasa tyk2. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20770904 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20770904 Country of ref document: EP Kind code of ref document: A2 |